On Friday 03/17/2023 the closing price of the IDEXX Laboratories share was $471.36 on NAS.
Compared to the opening price on Friday 03/17/2023 on NAS of $474.58, this is a drop of 0.68%.
IDEXX Laboratories's market capitalization is $38.57 B by 82.90 M shares outstanding.
Is IDEXX Laboratories stock a Buy, Sell or Hold?
IDEXX Laboratories stock has received a consensus rating of buy. The average rating score is and is based on 20 buy ratings, 3 hold ratings, and 0 sell ratings.What was the 52-week low for IDEXX Laboratories stock?
The low in the last 52 weeks of IDEXX Laboratories stock was 317.09. According to the current price, IDEXX Laboratories is 148.65% away from the 52-week low.What was the 52-week high for IDEXX Laboratories stock?
The high in the last 52 weeks of IDEXX Laboratories stock was 560.62. According to the current price, IDEXX Laboratories is 84.08% away from the 52-week high.What are analysts forecasts for IDEXX Laboratories stock?
The 23 analysts offering price forecasts for IDEXX Laboratories have a median target of 552.30, with a high estimate of 770.00 and a low estimate of 415.00. The median estimate represents a 85.34 difference from the last price of 471.36.IDEXX Laboratories Stock Snapshot
471.19
Bid
900.00
Bid Size
471.36
Ask
1,000.00
Ask Size
3/17/2023
Date
8:00 PM
Time
427,073.00
Volume
474.11
Prev. Close
474.58
Open
38.57 B
Market Cap
82.90 M
Number of Shares
466.33
Day Low
476.56
Day High
471.36
317.09
52 Week Low
560.62
52 Week High
471.36
0.00
Dividend
50.94
P/E Ratio
98.99
Free Float in %
9.65
EPS 2023
8.66
Book Value per Share
10.79
Cash Flow per Share
IDEXX Laboratories News More News
IDEXX Laboratories Historical Prices
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
IDEXX Laboratories Analyst Data
Total Analysts: 23
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 415.00
Median: 552.30
Highest: 770.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
IDEXX Laboratories Analyst Opinions
- All
- Buy
- Hold
- Sell
| 02/08/23 | Barclays Capital | Maintained Buy | $590 | ||
| 02/07/23 | J.P. Morgan | Maintained Buy | $550 | ||
| 02/07/23 | Atlantic Equities | Maintained Buy | $600 | ||
| 01/25/23 | Goldman Sachs | Maintained Buy | $530 | ||
| 11/15/22 | Morgan Stanley | Maintained Buy | $543 | ||
| 11/02/22 | Atlantic Equities | Maintained Buy | $470 | ||
| 10/17/22 | J.P. Morgan | Maintained Buy | $450 | ||
| 08/05/22 | Barclays Capital | Maintained Buy | $582 | ||
| 08/04/22 | Morgan Stanley | Maintained Buy | $573 | ||
| 08/03/22 | Atlantic Equities | Maintained Buy | $490 | ||
| 07/26/22 | Piper Sandler | Maintained Buy | $420 | ||
| 07/25/22 | Stifel, Nicolaus & Co., Inc. | Downgraded to Buy | $415 | ||
| 07/21/22 | Goldman Sachs | Upgraded to Buy | $435 | ||
| 07/12/22 | Piper Sandler | Maintained Buy | $440 | ||
| 06/24/22 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $500 | ||
| 05/19/22 | Goldman Sachs | Maintained Hold | $530 | ||
| 05/05/22 | Morgan Stanley | Maintained Buy | $603 | ||
| 05/05/22 | Bank of America Merrill Lynch | Downgraded to Hold | $470 | ||
| 02/08/22 | Atlantic Equities | Maintained Buy | $650 | ||
| 11/18/21 | Morgan Stanley | Maintained Buy | $732 | ||
| 08/13/21 | Credit Suisse | Maintained Buy | $770 | ||
| 08/03/21 | Goldman Sachs | Maintained Hold | $610 | ||
| 08/02/21 | Barclays Capital | Maintained Buy | $750 | ||
| 07/12/21 | Guggenheim | Downgraded to Hold |
IDEXX Laboratories Estimates* in USD
| 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|
| Revenue | 3,656 | 4,024 | 4,415 | 4,752 | 5,172 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (in %) | - | - | - | - | - |
| EPS | 9.65 | 11.05 | 12.67 | 14.40 | 16.91 |
| P/E Ratio | 49.46 | 43.19 | 37.68 | 33.15 | 28.23 |
| EBIT | 1,076 | 1,209 | 1,363 | 1,495 | 1,656 |
| EBITDA | 1,212 | 1,344 | 1,472 | 1,590 | 1,720 |
| Net Profit | 807 | 915 | 1,038 | 1,167 | 1,296 |
| Net Profit Adjusted | 806 | 914 | 1,062 | - | - |
| Pre-Tax Profit | 1,032 | 1,167 | 1,330 | 1,481 | 1,645 |
| Net Profit (Adjusted) | 1,029 | 1,168 | 1,333 | - | - |
| EPS (Non-GAAP) ex. SOE | 9.65 | 11.09 | 12.88 | 14.98 | 18.75 |
| EPS (GAAP) | 9.65 | 11.05 | 12.67 | 14.40 | 16.91 |
| Gross Income | 2,179 | 2,406 | 2,656 | 2,878 | 3,144 |
| Cash Flow from Investing | -63 | -48 | -56 | -161 | -173 |
| Cash Flow from Operations | 900 | 974 | 1,092 | 1,174 | 1,269 |
| Cash Flow from Financing | -575 | -1,003 | -798 | -728 | -793 |
| Cash Flow per Share | 10.79 | 12.34 | 13.83 | - | - |
| Free Cash Flow | 753 | 832 | 940 | - | - |
| Free Cash Flow per Share | 9.78 | 10.24 | - | - | - |
| Book Value per Share | 8.66 | 13.05 | 15.50 | - | - |
| Net Debt | 1,173 | 994 | 889 | - | - |
| Research & Development Exp. | 193 | 210 | 228 | 240 | 258 |
| Capital Expenditure | 179 | 171 | 169 | 161 | 173 |
| Selling, General & Admin. Exp. | 904 | 989 | 1,072 | - | - |
| Shareholder’s Equity | 796 | 1,173 | 1,540 | 2,316 | 2,856 |
| Total Assets | 3,043 | 3,015 | 3,314 | 3,643 | 4,139 |
|
Previous Quarter ending 12/31/22 |
Current Quarter ending 03/31/23 |
Next Quarter ending 06/30/23 |
Current Year ending 12/31/23 |
Next Year ending 12/31/24 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 11 | 9 | 9 | 11 | 11 |
| Average Estimate | 1.924 USD | 2.433 USD | 2.518 USD | 9.651 USD | 11.052 USD |
| Year Ago | 1.890 USD | 2.270 USD | 1.560 USD | 8.030 USD | 9.651 USD |
| Publish Date | 2/6/2023 | 5/3/2023 | 8/1/2023 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 8 | 8 | 8 | 9 | 9 |
| Average Estimate | 821 USD | 891 USD | 931 USD | 3,656 USD | 4,024 USD |
| Year Ago | 801 USD | 837 USD | 861 USD | 3,367 USD | 3,656 USD |
| Publish Date | 2/6/2023 | 5/3/2023 | 8/1/2023 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
IDEXX Laboratories Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| JUNIUS DANIEL M | 02/15/2023 | 2,187.00 | 2,982.00 | 511.68 | Sell | No |
| Turner Kathy V | 02/15/2023 | 10.00 | 7,379.85 | 515.58 | Sell | No |
| AYERS JONATHAN W | 02/15/2023 | 1,000.00 | 145,520.00 | n/a | Sell | No |
| JUNIUS DANIEL M | 02/15/2023 | 2,187.00 | 5,169.00 | 206.62 | Buy | No |
| Turner Kathy V | 02/15/2023 | 10.00 | 7,389.85 | 79.54 | Buy | No |
| Turner Kathy V | 02/14/2023 | 1,000.00 | 7,379.85 | 510.03 | Sell | No |
| Turner Kathy V | 02/14/2023 | 1,000.00 | 8,379.85 | 79.54 | Buy | No |
| MCKEON BRIAN P | 02/13/2023 | 1,208.00 | 29,030.64 | 503.65 | Sell | No |
| Turner Kathy V | 02/13/2023 | 110.00 | 7,379.85 | 502.81 | Sell | No |
| Turner Kathy V | 02/13/2023 | 577.00 | 7,489.85 | 504.09 | Sell | No |
| Turner Kathy V | 02/13/2023 | 313.00 | 8,066.85 | 504.66 | Sell | No |
| Turner Kathy V | 02/13/2023 | 1,000.00 | 8,379.85 | 505.06 | Sell | No |
| Turner Kathy V | 02/13/2023 | 293.00 | 7,379.85 | 503.65 | Sell | No |
| MAZELSKY JAY | 02/13/2023 | 1,657.00 | 72,726.64 | 503.65 | Sell | No |
| Underberg Sharon E. | 02/13/2023 | 305.00 | 3,746.99 | 503.65 | Sell | No |
| Lane Michael | 02/13/2023 | 275.00 | 5,007.28 | 503.65 | Sell | No |
| Hunt Nimrata | 02/13/2023 | 239.00 | 11,015.28 | 503.65 | Sell | No |
| MCKEON BRIAN P | 02/13/2023 | 303.00 | 30,238.64 | n/a | Buy | No |
| MCKEON BRIAN P | 02/13/2023 | 253.00 | 29,935.64 | n/a | Buy | No |
| MCKEON BRIAN P | 02/13/2023 | 433.00 | 29,682.64 | n/a | Buy | No |
| MCKEON BRIAN P | 02/13/2023 | 435.00 | 29,249.64 | n/a | Buy | No |
| MCKEON BRIAN P | 02/13/2023 | 504.00 | 28,814.64 | n/a | Buy | No |
| Turner Kathy V | 02/13/2023 | 2,000.00 | 9,379.85 | 79.54 | Buy | No |
| Turner Kathy V | 02/13/2023 | 93.00 | 7,672.85 | n/a | Buy | No |
| Turner Kathy V | 02/13/2023 | 86.00 | 7,579.95 | n/a | Buy | No |
IDEXX Laboratories Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2022 | IDEXX Laboratories | - | - | USD |
| 2021 | IDEXX Laboratories | - | - | USD |
| 2020 | IDEXX Laboratories | - | - | USD |
| 2019 | IDEXX Laboratories | - | - | USD |
| 2018 | IDEXX Laboratories | - | - | USD |
| 2017 | IDEXX Laboratories | - | - | USD |
| 2016 | IDEXX Laboratories | - | - | USD |
| 2015 | IDEXX Laboratories | - | - | USD |
| 2014 | IDEXX Laboratories | - | - | USD |
| 2013 | IDEXX Laboratories | - | - | USD |
| 2012 | IDEXX Laboratories | - | - | USD |
| 2011 | IDEXX Laboratories | - | - | USD |
| 2010 | IDEXX Laboratories | - | - | USD |
| 2009 | IDEXX Laboratories | - | - | USD |
*Yield of the Respective Date
IDEXX Laboratories Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 2.433 USD | Q1 2023 Earnings Release | 05/03/2023 |
| Earnings Report | 2.518 USD | Q2 2023 Earnings Release | 08/01/2023 |
| Earnings Report | - | Q3 2023 Earnings Release | 10/31/2023 |
| Earnings Report | - | Q4 2023 Earnings Release | 01/31/2024 |
IDEXX Laboratories Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 2.050 USD | Q4 2022 Earnings Release | 02/06/2023 |
| Shareholders' Meeting | - | - | 05/11/2022 |
IDEXX Laboratories Profile
IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.
Moody’s Daily Credit Risk Score
IDEXX Laboratories Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.00 |
| Vanguard Group, Inc. (Subfiler) | 9.39 |
| State Street Corp. | 4.62 |
| Fundsmith LLP | 4.15 |
| Fundsmith Equity Fund | 4.11 |
| AllianceBernstein LP | 3.91 |
| BlackRock Fund Advisors | 3.73 |
| Vanguard Total Stock Market Index Fund | 3.08 |
| BAMCO, Inc. | 2.86 |
| BlackRock Institutional Trust Co. NA | 2.42 |
| Geode Capital Management LLC | 2.32 |
| Vanguard 500 Index Fund | 2.32 |
| American Century Cos., Inc. | 1.82 |
| William Blair & Co. LLC | 1.45 |
| Franklin Advisers, Inc. | 1.38 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
IDEXX Laboratories Management
| Name | Job |
|---|---|
| James F. Polewaczyk | Chief Commercial Officer & Executive VP |
| Brian Patrick McKeon | Chief Financial Officer, Treasurer & Executive VP |
| Michael P. Johnson | Chief Human Resources Officer & Senior VP |
| Ken Grady | Chief Information Officer & Senior VP |
| Martin Alexander Smith | Chief Technology Officer & Executive VP |
| Jonathan W. Ayers | Director |
| Michael J. Lane | Executive VP & GM-Reference Laboratories |
| Tina Hunt | Executive Vice President-Strategy |
| Bruce L. Claflin | Independent Director |
| Daniel M. Junius | Independent Director |
| Asha S. Collins | Independent Director |
| Sam A. Samad | Independent Director |
| Stuart M. Essig | Independent Director |
| M. Anne Szostak | Independent Director |
| Sophie V. Vandebroek | Independent Non-Executive Director |
| John Ravis | Investor Relations Contact |
| Lawrence D. Kingsley | Non-Executive Chairman |
| Jonathan J. Mazelsky | President, Chief Executive Officer & Director |
| Michael Erickson | SVP & GM-Point of Care Diagnostics |
| Sharon E. Underberg | Secretary, Executive VP & General Counsel |
| Kathy V. Turner | Senior Vice President |
| John Hart | Senior Vice President-Global Operations |
| Murthy Yerramilli | Senior Vice President-Research & Development |
| George J. Fennell | Vice President |